Diabetes and Drug-Eluting Stents. What You Get and What You Don't**Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.

JACC: Cardiovascular Interventions

Volumn 1, Issue 2, 2008, Pages 148-149

  Marso, Steven P ^a  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PACLITAXEL; RAPAMYCIN;

CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; IN-STENT RESTENOSIS; MORTALITY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG-ELUTING STENTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METALS; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; RISK ASSESSMENT; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 41949094221     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.02.004     Document Type: Editorial

References (15)

1. Faxon D.P., Detre K.M., McCabe C.H., et al. Role of percutaneous transluminal coronary angioplasty in the treatment of unstable angina. Report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Surgery Study Registries. Am J Cardiol 53 (1984) 131C-135C
2. Mulukutla S.R., Vlachos H.A., Marroquin O.C., et al. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol Intv 1 (2008) 139-147
3. Marso S.P., Giorgi L.V., Johnson W.L., et al. Diabetes mellitus is associated with a shift in the temporal risk profile of in hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. Am Heart J 145 (2003) 270-277
4. Frutkin A.D., Mehta S.K., House J.A., et al. The use of percutaneous coronary intervention in patients with class i indications for coronary artery bypass graft surgery: data from the National Cardiovascular Data Registry. Circulation 116 (2007) II795
5. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
6. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
7. Camenzind E. Safety of Drug-Eluting Stents: Insights from a Meta-Analysis. Presented at: European Society of Cardiology World Cardiology Congress, Barcelona, Spain: September 5, 2006.
8. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
9. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
10. Kastrati A., Dibra A., Spaulding C., et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28 (2007) 2706-2713
11. Pasceri V., Patti G., Speciale G., et al. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153 (2007) 749-754
12. Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
13. Sabate M., Jimenez-Quevedo P., Angiolillo D.J., et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
14. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
15. Boyden T.F., Nallamothu B.K., Moscucci M., et al. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 99 (2007) 1399-1402